Coherus Oncology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M |
| Operating income | -$181.1M | -$199.7M | -$203.2M | -$256.9M | -$263.9M |
| Cost of revenue | $13.8M | $8.7M | $159.0M | $70.1M | $57.6M |
| Cash from operations | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$37.4M |
| Capital expenditure | — | — | $286,000 | $2.0M | $1.3M |
| Free cash flow | — | — | -$175.2M | -$243.2M | -$38.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $258.3M | $448.5M | $629.6M | $480.8M | $679.3M |
| Total liabilities | $197.3M | $580.5M | $823.0M | $618.3M | $581.6M |
Shares outstanding 154.2M · Free float 95.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.